Poolbeg Pharma (STU:7JN) Debt-to-Asset : 0.00 (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Poolbeg Pharma Debt-to-Asset?

Poolbeg Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €0.00 Mil. Poolbeg Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €0.00 Mil. Poolbeg Pharma's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2024 was €15.38 Mil. Poolbeg Pharma's debt to asset for the quarter that ended in Jun. 2024 was 0.00.

Poolbeg Pharma Debt-to-Asset Historical Data

The historical data trend for Poolbeg Pharma's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Poolbeg Pharma Debt-to-Asset Chart

Poolbeg Pharma Annual Data

Trend

Dec21

Dec22

Dec23

Debt-to-Asset

Poolbeg Pharma Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Debt-to-Asset	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Poolbeg Pharma's Debt-to-Asset

For the Biotechnology subindustry, Poolbeg Pharma's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Poolbeg Pharma's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Poolbeg Pharma's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Poolbeg Pharma's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Poolbeg Pharma Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Poolbeg Pharma's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	17.908
	=	0.00

Poolbeg Pharma's Debt-to-Asset for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	15.377
	=	0.00

Poolbeg Pharma (STU:7JN) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Poolbeg Pharma Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Poolbeg Pharma's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Poolbeg Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Poolbeg Pharma PLC (STU:7JN) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

POLB:UK 7JN:Germany

Address

42 New Road, Queen Mary BioEnterprises Innovation Centre, London, GBR, E1 2AX

Website

https://www.poolbegpharma.com

Poolbeg Pharma PLC is a clinical-stage infectious disease pharmaceutical company, with a novel capital-light clinical model which enables to develop of multiple products faster and more cost-effectively than the traditional biotech model. The company aspires to become a one-stop shop for pharma-seeking mid-stage products to license or acquire.

Poolbeg Pharma Headlines

No Headlines